These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 13129985)

  • 1. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial.
    O'Connor CM; Dunne MW; Pfeffer MA; Muhlestein JB; Yao L; Gupta S; Benner RJ; Fisher MR; Cook TD;
    JAMA; 2003 Sep; 290(11):1459-66. PubMed ID: 13129985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azithromycin for the secondary prevention of coronary events.
    Grayston JT; Kronmal RA; Jackson LA; Parisi AF; Muhlestein JB; Cohen JD; Rogers WJ; Crouse JR; Borrowdale SL; Schron E; Knirsch C;
    N Engl J Med; 2005 Apr; 352(16):1637-45. PubMed ID: 15843666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study.
    Muhlestein JB; Anderson JL; Carlquist JF; Salunkhe K; Horne BD; Pearson RR; Bunch TJ; Allen A; Trehan S; Nielson C
    Circulation; 2000 Oct; 102(15):1755-60. PubMed ID: 11023928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial.
    Dunne MW
    J Infect Dis; 2000 Jun; 181 Suppl 3():S572-8. PubMed ID: 10839762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Description and status of the azithromycin and coronary events study (ACES).
    Jackson LA
    J Infect Dis; 2000 Jun; 181 Suppl 3():S579-81. PubMed ID: 10839763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary prevention of atherosclerosis through chlamydia pneumoniae eradication (SPACE Trial): a randomised clinical trial in patients with peripheral arterial disease.
    Vainas T; Stassen FR; Schurink GW; Tordoir JH; Welten RJ; van den Akker LH; Kurvers HA; Bruggeman CA; Kitslaar PJ
    Eur J Vasc Endovasc Surg; 2005 Apr; 29(4):403-11. PubMed ID: 15749042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial.
    Cercek B; Shah PK; Noc M; Zahger D; Zeymer U; Matetzky S; Maurer G; Mahrer P;
    Lancet; 2003 Mar; 361(9360):809-13. PubMed ID: 12642046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study.
    Anderson JL; Muhlestein JB; Carlquist J; Allen A; Trehan S; Nielson C; Hall S; Brady J; Egger M; Horne B; Lim T
    Circulation; 1999 Mar; 99(12):1540-7. PubMed ID: 10096928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: A double-blind, randomized, placebo-controlled study.
    Hillis GS; Pearson CV; Harding SA; Sutherland S; Ludlam CA; Marioni JC; Prescott RJ; Fox KA; Flapan AD
    Am Heart J; 2004 Jul; 148(1):72-9. PubMed ID: 15215794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA).
    Stone AF; Mendall MA; Kaski JC; Edger TM; Risley P; Poloniecki J; Camm AJ; Northfield TC
    Circulation; 2002 Sep; 106(10):1219-23. PubMed ID: 12208796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome.
    Cannon CP; Braunwald E; McCabe CH; Grayston JT; Muhlestein B; Giugliano RP; Cairns R; Skene AM;
    N Engl J Med; 2005 Apr; 352(16):1646-54. PubMed ID: 15843667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction.
    Gupta S; Leatham EW; Carrington D; Mendall MA; Kaski JC; Camm AJ
    Circulation; 1997 Jul; 96(2):404-7. PubMed ID: 9244203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ACADEMIC study in perspective (Azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia).
    Anderson JL; Muhlestein JB
    J Infect Dis; 2000 Jun; 181 Suppl 3():S569-71. PubMed ID: 10839761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic treatment of atherosclerosis.
    Muhlestein JB
    Curr Opin Lipidol; 2003 Dec; 14(6):605-14. PubMed ID: 14624138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection.
    Parchure N; Zouridakis EG; Kaski JC
    Circulation; 2002 Mar; 105(11):1298-303. PubMed ID: 11901039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae.
    Rothstein NM; Quinn TC; Madico G; Gaydos CA; Lowenstein CJ
    J Infect Dis; 2001 Jan; 183(2):232-238. PubMed ID: 11120929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial.
    Leowattana W; Bhuripanyo K; Singhaviranon L; Akaniroj S; Mahanonda N; Samranthin M; Pokum S
    J Med Assoc Thai; 2001 Dec; 84 Suppl 3():S669-75. PubMed ID: 12002908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azithromycin for the secondary prevention of coronary artery disease: a meta-analysis.
    Baker WL; Couch KA
    Am J Health Syst Pharm; 2007 Apr; 64(8):830-6. PubMed ID: 17420199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chlamydia pneumoniae infection in Slovenian patients with diffuse coronary artery disease.
    Zorc M; Kese D; Petrovic D; Legan M
    Med Arh; 2004; 58(6):331-4. PubMed ID: 15648226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease.
    Jackson LA; Stewart DK; Wang SP; Cooke DB; Cantrell T; Grayston JT
    J Antimicrob Chemother; 1999 Sep; 44(3):411-4. PubMed ID: 10511413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.